Ucore Secures Additional US$4.6 Million from U.S. Department of War to Advance Samarium and Gadolinium Refining

Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) received an additional US$4.6 million from the U.S. Department of War to expand its RapidSX™ program for samarium and gadolinium refining. The total funding now stands at US$27.0 million. The company aims to support critical defense supply chains amid heightened interest from Washington. Ucore is developing separation capabilities for rare earth materials identified as priorities by the U.S. government.

Original reporting
Published Sep 14, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ucore Secures Additional US$4.6 Million from U.S. Department of War to Advance Samarium and Gadolinium Refining — source image
Decision brief

The 30-second read

$UURAFBullishMed
01

Why it matters

The infusion of federal money de‑risks the company's commercial rollout, likely improving investor sentiment and providing a catalyst for the stock.

02

Market read

The award highlights growing U.S. focus on domestic critical minerals, potentially benefiting the broader rare‑earth and defense supply chain sectors.

03

What to watch

Future U.S. policy changes or budget cuts could reduce additional funding beyond the current award.

Relevance 7/10Novelty 7/10Timing: today

Background

Ucore Rare Metals announced a $4.6M grant from the U.S. Department of War to expand its RapidSX™ rare‑earth separation program, bringing total OTA funding to $27M for its Louisiana facility.

Company-level read

Ticker impact

$UURAFBullishMedium confidence
Context

Ucore Rare Metals received an additional $4.6M Other Transaction Agreement from the U.S. Department of War, raising total grant funding to $27M.

Expected impact

Potential upside as the funding reduces financing risk and may boost share price.

Evidence & confidence

The award confirms U.S. demand for domestic rare‑earth supply, improving the company's growth outlook.

Market effects

Strengthens the U.S. defense and critical‑minerals sector by adding domestic rare‑earth processing capacity.

Boosts U.S. and Canadian rare‑earth supply chains and may attract further regional funding.

Supports global diversification away from China‑dominated rare‑earth supply.

Counterpoint

If the program faces technical delays, the funding may not translate into near‑term revenue, limiting stock upside.

Key entities

  • Ucore Rare Metals Inc.

    TSXV‑listed rare‑earth developer receiving the grant.

  • U.S. Department of War

    Provides the $4.6M Other Transaction Agreement to fund rare‑earth processing.

  • RapidSX™ program

    Ucore's rare‑earth separation technology platform.

Related articles

$UURAFMed

US South builds a rare earth supply chain

Aclara Resources (ARA) and other companies are developing rare earth processing plants in the U.S. South, aiming to reduce dependence on China. Aclara plans a $494M plant in Louisiana, with potential $750M financing. Rare Earths Americas (REA) is exploring deposits in Georgia. Both companies' shares fell recently. The region's infrastructure and government support are key to these projects' success.

$UURAFMedAI 8/10

Ucore Rare Metals, Inc.: Ucore Announces $60 Million Bought Deal Public Offering of Common Shares

Ucore Rare Metals Inc. (TSX-V:UCU, OTCQX:UURAF) announced a bought deal public offering of 21.43 million common shares at C$2.80 each for gross proceeds of about C$60.0 million. Underwriters include Red Cloud Securities and B. Riley Securities. Net proceeds will fund development of Louisiana’s strategic metals complex and working capital. Closing is expected around Aug. 13, 2026.

$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.